医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

3D Printing 2018_Japan, Brings You the Latest Information on the Cutting Edge Technology for 3D Printing and Additive Manufacturing

2018年02月01日 AM10:00
このエントリーをはてなブックマークに追加


 

TOKYO

The JTB Communication Design, Inc. will be holding “3D Printing 2018” – the Cutting Edge 3D Printing Technologies exhibitions, now in its 4th year – on February 14th -16th, 2018, at the Tokyo Big Sight convention center in Japan.
We’ve seen huge growth since 3D Printing begun, with over 140% more exhibitors set to attend than in 2015.
86 organizations (including over 39 first-time exhibitors) from 7 countries and regions are set to exhibit at the event in 146 booths (about 1,500sqm), demonstrating revolutionary and cutting edge core technologies.
The total number of visitors to the event are expected to exceed 50,000 with 10 co-exhibitions.

Don’t miss this chance to catch up with the latest developments in the 3D Printing world!

3D Printing 2018 Additive Manufacturing Technology Exhibition
Date: February 14-16, 2018, 10:00-17:00
Venue: Tokyo Big Sight (East Halls 6)
Organizer: JTB Communication Design, Inc

For more detail, please visit our official web site.
Register to visit here:

Or print out this invitation and bring it with you for free access
>> http://www.nanotechexpo.jp/JCD/3dprinting2018_invitation.pdf

View source version on businesswire.com: http://www.businesswire.com/news/home/20180131005606/en/

CONTACT

Secretariat of 3D Printing (c/o JTB Communication Design)
Mr.
Masaya Yamagata, +81-3-5657-0760
3dpritning@jtbcom.co.jp

同じカテゴリーの記事 

  • The 11th BioCentury-BayHelix China Healthcare Summit: Reinvent Your Global Drug Development Strategy in Shanghai
  • NAMSA and TERUMO Announce Strategic Outsourcing Partnership
  • Airway Therapeutics to Launch a Multinational Phase 3 Trial of Zelpultide Alfa for Preterm Neonates at Risk of Bronchopulmonary Dysplasia
  • NSF Celebrates 80 Years of Improving Human and Planet Health
  • Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease